Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04047030 · ClinicalTrials.gov registry record
The Mobility Toolkit: Electronically Augmented Assessment of Functional Recovery Following Lower-extremity Trauma
A clinical trial, sponsored by Major Extremity Trauma Research Consortium.
- Completed
- Registry status
- 244
- Enrollment target
NCT04047030: Completed study, sponsored by Major Extremity Trauma Research Consortium.
NCT04047030 is a clinical trial that has completed, run by Major Extremity Trauma Research Consortium. The registered enrollment target is 244 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04047030 has completed, sponsored by Major Extremity Trauma Research Consortium.
- COMPLETED
- Registry status
- 244 participants
- Enrollment target
Study Summary
The study will prospectively enroll and follow 300 participants ages 18-60 surgically treated for a lower-extremity articular injury including fractures of the tibial plateau, pilon, ankle, and calcaneus.
Primary Outcome
Feasibility will be assessed through surveys of study participants and clinical staff to document time and burden of using MTK during clinic visits.
Interventions
- OTHER None- Observational Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2024-08-31 |
What the finished NCT04047030 record still lists
NCT04047030 is an observational study that tracks outcomes without assigning an intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which None- Observational Study is the first listed.
NCT04047030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04047030 about?
NCT04047030 is a clinical study titled "The Mobility Toolkit: Electronically Augmented Assessment of Functional Recovery Following Lower-extremity Trauma". The study will prospectively enroll and follow 300 participants ages 18-60 surgically treated for a lower-extremity articular injury including fractures of the tibial plateau, pilon, ankle, and calcaneus.
What is the current status of trial NCT04047030?
This trial is currently completed. The enrollment target is 244 participants. The study started on 2019-01-01. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT04047030?
The interventions under investigation include: None- Observational Study (OTHER).
Who is sponsoring clinical trial NCT04047030?
This trial is sponsored by Major Extremity Trauma Research Consortium, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI